Afficher la notice abrégée

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAVINA, Marion
dc.contributor.authorGOURGOU, S.
dc.contributor.authorITALIANO, A.
dc.contributor.authorDINART, D.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRONDEAU, Virginie
dc.contributor.authorPENEL, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2021-01-05T08:32:59Z
dc.date.available2021-01-05T08:32:59Z
dc.date.issued2018-03
dc.identifier.issn1879-0461 (Electronic) 1040-8428 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23640
dc.description.abstractEnBACKGROUND: In cancer randomized controlled trials (RCT), alternative endpoints are increasingly being used in place of overall survival (OS) to reduce sample size, duration and cost of trials. It is necessary to ensure that these endpoints are valid surrogates for OS. Our aim was to identify meta-analyses that evaluated surrogate endpoints for OS and assess the strength of evidence for each meta-analysis (MA). MATERIALS AND METHODS: We performed a systematic review to identify MA of cancer RCTs assessing surrogate endpoints for OS. We evaluated the strength of the association between the endpoints based on (i) the German Institute of Quality and Efficiency in Health Care guidelines and (ii) the Biomarker-Surrogate Evaluation Schema. RESULTS: Fifty-three publications reported on 164 MA, with heterogeneous statistical methods Disease-free survival (DFS) and progression-free survival (PFS) showed good surrogacy properties for OS in colorectal, lung and head and neck cancers. DFS was highly correlated to OS in gastric cancer. CONCLUSION(S): The statistical methodology used to evaluate surrogate endpoints requires consistency in order to facilitate the accurate interpretation of the results. Despite the limited number of clinical settings with validated surrogate endpoints for OS, there is evidence of good surrogacy for DFS and PFS in tumor types that account for a large proportion of cancer cases.
dc.language.isoENen_US
dc.subject.enBiostatistics
dc.subject.enCIC1401
dc.subject.enEPICENE
dc.title.enMeta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review
dc.title.alternativeCrit Rev Oncol Hematolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.critrevonc.2017.11.014en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29482777en_US
bordeaux.journalCritical Reviews in Oncology/Hematologyen_US
bordeaux.page21-41en_US
bordeaux.volume123en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.teamBIOSTAT_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03193002
hal.version1
hal.date.transferred2021-04-08T13:03:24Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Critical%20Reviews%20in%20Oncology/Hematology&rft.date=2018-03&rft.volume=123&rft.spage=21-41&rft.epage=21-41&rft.eissn=1879-0461%20(Electronic)%201040-8428%20(Linking)&rft.issn=1879-0461%20(Electronic)%201040-8428%20(Linking)&rft.au=SAVINA,%20Marion&GOURGOU,%20S.&ITALIANO,%20A.&DINART,%20D.&RONDEAU,%20Virginie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée